Cargando…

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneity. We interrogated transcriptomics of 15 TPMs (CD137, CD27,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyashita, Hirotaka, Kurzrock, Razelle, Bevins, Nicholas J., Thangathurai, Kartheeswaran, Lee, Suzanna, Pabla, Sarabjot, Nesline, Mary, Glenn, Sean T., Conroy, Jeffrey M., DePietro, Paul, Rubin, Eitan, Sicklick, Jason K., Kato, Shumei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409760/ https://www.ncbi.nlm.nih.gov/pubmed/37553332 http://dx.doi.org/10.1038/s41525-023-00359-8

Ejemplares similares

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy
por: Jou, Jessica, et al.
Publicado: (2023)

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
por: Adashek, Jacob J., et al.
Publicado: (2023)

Immune profiling and immunotherapeutic targets in pancreatic cancer
por: Lenzo, Felicia L., et al.
Publicado: (2021)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
por: Kato, Shumei, et al.
Publicado: (2021)

Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
por: Kato, Shumei, et al.
Publicado: (2021)

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
por: Bohan, Sandy S., et al.
Publicado: (2020)

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
por: Okamura, Ryosuke, et al.
Publicado: (2021)

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
por: Gupta, Diviya, et al.
Publicado: (2022)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase
por: Geifman, Nophar, et al.
Publicado: (2014)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
por: Nesline, Mary K., et al.
Publicado: (2023)

Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
por: Louie, Bryan H., et al.
Publicado: (2022)

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
por: Persha, Hanna E., et al.
Publicado: (2022)

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
por: Shaya, Justin, et al.
Publicado: (2023)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors
por: Conroy, Jeffrey M., et al.
Publicado: (2021)

Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response
por: Pabla, Sarabjot, et al.
Publicado: (2021)

Immunome Research
por: Petrovsky, Nikolai
Publicado: (2005)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Immunome Knowledge Base (IKB): An integrated service for immunome research
por: Ortutay, Csaba, et al.
Publicado: (2009)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome
por: Teltsh, Omri, et al.
Publicado: (2015)

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
por: Krishnamurthy, Nithya, et al.
Publicado: (2022)

Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay
por: Pabla, Sarabjot, et al.
Publicado: (2019)

The Conundrum of Genetic “Drivers” in Benign Conditions
por: Kato, Shumei, et al.
Publicado: (2016)

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
por: Kato, Shumei, et al.
Publicado: (2019)

Dermatologic Disease-Directed Targeted Therapy (D(3)T(2)): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology
por: Cohen, Philip R., et al.
Publicado: (2022)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Immunome database for marsupials and monotremes
por: Wong, Emily SW, et al.
Publicado: (2011)

Immunomics in inflammatory rheumatic diseases
por: Konthur, Z, et al.
Publicado: (2004)

Immunomics in Pediatric Rheumatic Diseases
por: Tay, Shi Huan, et al.
Publicado: (2019)

The Future of Blood Testing Is the Immunome
por: Arnaout, Ramy A., et al.
Publicado: (2021)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d19lrvm5habll0b1fm2u83mia4